Clinical efficacy of immunotherapy combined with chemotherapy in patients with advanced gastric cancer, its effect on nutritional status and Changes of peripheral blood T lymphocyte subsets.

Jin Jiao,Wen-Wen Li,Ya-Ning Wei,Yuan-Fang Zhang,Zhi-Yu Wang

doi:10.12669/pjms.37.7.4347

Jin Jiao, Wen-Wen Li + Show 3 more

Open Access

https://doi.org/10.12669/pjms.37.7.4347

Copy DOI

Abstract

Objectives:To evaluate the clinical efficacy of immunotherapy combined with chemotherapy in patients with advanced gastric cancer and its effect on nutritional status and changes of peripheral blood T lymphocyte subsets.Methods:Sixty patients with locally advanced gastric cancer who were admitted by Affiliated Hospital of Hebei University from March 2020 to February 2021 were enrolled and randomly divided into two groups, with 30 cases in each group. The control group was treated with FOLFOX4 chemotherapy, while the experimental group was additively treated with cindilizumab on the basis of control group. The incidence of adverse reactions, clinical efficacy, improvement of nutritional and physical status, and changes in the levels of T lymphocyte subgroups in the two groups were compared and analyzed.Results:The total effective rate was 70% in the experimental group, which was better than 43.3% of the control group (p=0.04). The improvement rate of performance status (ECOG) score and nutritional indicators in the experimental group was significantly better than that in the control group (p<0.05). Moreover, the indicators of CD3+, CD4+, CD4+/CD8+ in the experimental group were significantly higher than those in the control group after treatment, with statistically significant differences (CD3+, p=0.01; CD4 +, p= 0.02; CD4+/CD8+, p=0.01).Conclusion:Immunotherapy combined with chemotherapy has a significant effect on locally advanced gastric cancer patients, with significant improvement in physical strength and nutritional status, significant improvement in T lymphocyte function, and no obvious adverse reactions. It is worth promoting in clinical application.

Highlights

Gastric cancer, as one of the most common malignant tumors of the digestive tract, features an extremely low overall survival rate.[1]
Immunotherapy combined with chemotherapy was used to treat locally advanced gastric cancer patients to observe the efficacy of this combined therapy and the effects on the immune function, physical status and nutritional status of the patients
The comparative analysis of the treatment effect of the two groups is shown in Table-II, suggesting that the total effective rate of the experimental group was 70% after treatment, which was significantly better than the 43.3% of the control group, with a statistically significant difference (p=0.04)

Summary

Introduction

As one of the most common malignant tumors of the digestive tract, features an extremely low overall survival rate.[1]. Palliative gastrectomy, chemoradiotherapy,[3] molecular targeted therapy and immunotherapy[4] are the main treatment methods for advanced gastric cancer. It has been shown in recent domestic and foreign studies that for patients with advanced malignant tumors who receive immunotherapy regimen, their inflammatory response can be decreased, the level of tumor markers will be reduced, and the immune function of T lymphocytes can be improved.[5] In this study, immunotherapy combined with chemotherapy was used to treat locally advanced gastric cancer patients to observe the efficacy of this combined therapy and the effects on the immune function, physical status and nutritional status of the patients

Objectives

Methods

Results

Conclusion